Sanofi Sponsored ADR Aktie News

Sanofi faces a setback as tolebrutinib fails its Phase 3 PPMS trial, halting regulatory pursuit for this indication. Meanwhile, an approval decision on the candidate has also been delayed. SNY's growth remains robust, with Q3 sales up 7% YoY, net income up 10%, and Dupixent driving ~35% of total revenues. Despite pipeline disappointments, SNY expects high single-digit sales and low-double-digit...

Dren Bio, a private biotech company, said on Monday it has entered into a strategic collaboration with Sanofi to develop therapies for autoimmune diseases in a deal worth up to $1.7 billion.

SAN CARLOS, Calif.--(BUSINESS WIRE)--Dren Bio Expands Strategic Collaboration with Sanofi to Develop Next-Generation B-Cell Depletion Therapy.

Shares of French pharmaceutical group Sanofi fell sharply on Monday after the company flagged another delay to a US regulatory decision for its experimental multiple sclerosis drug tolebrutinib and reported disappointing results from a late-stage clinical trial.

Shares of Sanofi slumped on Monday as the French drugmaker said a U.S. regulatory review of its multiple-sclerosis drug won't be completed by the end of the year and that a trial for a different form of MS didn't succeed.

French pharmaceutical group Sanofi said on Monday the U.S. Food and Drug Administration's decision on its investigative drug to treat multiple sclerosis was expected to be delayed until the first quarter of 2026, from the previously communicated December 28.

A U.S. regulatory decision on tolebrutinib will again be delayed while a late-stage trial of the drug for a different form of the disease didn't hit its main goal.

Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to onset of 6-month composite confirmed disability progression compared to placebo The safety profile of tolebrutinib was consistent with previous studies Paris, December 15, 2025. Results from the PER...